Physician profile
Brian Eades
NPI 1538151170
$54,898.38
in general payments reported to CMS, 2019-2025
40 companies · $4,850 in 2025
The $4,850 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $7,290 · 2021: $13K · 2022: $10K · 2023: $8,601 · 2024: $10K · 2025: $4,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $5,853 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,967.50 |
| Food and Beverage | $5,853.31 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45,098.32 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $3,287.43 | 2019-2025 | Jot Dx, Gallant, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $899.24 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $863.33 | 2021-2025 | Verquvo, Capvaxive |
| Cardiovascular Systems INC. | $754.91 | 2019-2020 | |
| Novo Nordisk INC | $519.37 | 2021-2025 | Ozempic, Rybelsus |
| Itamar Medical INC | $497.26 | 2021-2024 | Watchpatone |
| Astrazeneca Pharmaceuticals Lp | $262.38 | 2019-2025 | Farxiga |
| Heartflow, INC. | $240.76 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.94 | 2019-2025 | Evkeeza |
| Amarin Pharma, INC. | $197.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $179.08 | 2019-2024 | Xarelto |
| Medtronic, INC. | $178.63 | 2023 | Corevalve Evolut R |
| Esperion Therapeutics, INC. | $174.27 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.75 | 2019-2024 | Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $149.09 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Vifor Pharma, INC. | $136.68 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $117.77 | 2021-2025 | |
| Recor Medical INC | $116.68 | 2025 | Paradise Ultrasound Renal Denervation System |
| Pfizer INC. | $76.67 | 2020-2025 | |
| Scpharmaceuticals INC. | $70.43 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $69.41 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.17 | 2021-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $62.53 | 2019-2024 | |
| Cvrx, INC. | $55.99 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $44.37 | 2023 | Inpefa |
| Astellas Pharma US INC | $43.56 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $37.34 | 2025 | Assure Wcd |
| Aurinia Pharma U.S., INC. | $34.03 | 2021 | |
| Shockwave Medical, INC | $33.30 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $27.72 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biotronik INC. | $21.83 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $20.56 | 2019 | |
| Chiesi USA, INC. | $16.02 | 2020 | |
| Irhythm Technologies, INC. | $15.18 | 2021 | |
| Inspire Medical Systems, INC. | $14.35 | 2025 | Inspire |
| Baxter Healthcare | $13.09 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Digirad Health, INC | $11.55 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Eades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.